Real-world use of eravacycline for the treatment of mono- and polymicrobial infections involving Enterobacterales
Abstract
Bacterial species in the Enterobacterales order are commonly encountered causative organisms in hospital-acquired infections. Furthermore, the incidence of carbapenem-resistant Enterobacterales (CRE) is a growing threat worldwide. Eravacycline (ERV) is a broad-spectrum fluorocycline antibiotic with activity against Enterobacterales, including CRE, and is approved for the treatment of complicated intra-abdominal infections (cIAI) in the United States and Europe. We conducted a subpopulation analysis of a previously published real-world study evaluating the efficacy of eravacycline for the treatment of infections involving Enterobacterales. Adult patients who received eravacycline for ≥72 h for any infection type involving an Enterobacterales organism were included. The primary outcome was clinical success, and secondary outcomes comprised 30-day all-cause and in-hospital mortality, 30-day microbiological and symptomatic recurrence, and 30- and 60-day hospital readmission. A total of 155 patients were eligible for inclusion. The primary causative organisms were Klebsiella pneumoniae (34.2%), Escherichia coli (32.9%), and Enterobacter cloacae (31.3%), and 23.9% were CRE. A majority of infections (77.4%) were polymicrobial. The most common infection types were intra-abdominal (34.8%), skin and soft tissue (25.2%), and pneumonia (17.4%). The predominant rationale for ERV use was consolidation of the antibiotic regimen (56.8%), and the median (interquartile range) ERV duration was…
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.